Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies HAYWARD, Calif., January 21 ...

Arcus Biosciences (RCUS) announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer effective January 31, 2025. Dr.

Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Arcus Biosciences Inc . (NYSE:RCUS) stock has reached a 52-week low, touching down at $13.48. This latest price movement ...

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies Arcus Biosciences, Inc ...

Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer. The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled ...

SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...

Hayward, CA-based Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company with a market capitalization of $1.29 billion and a strong financial health rating according to ...